Article content
- Builds on the existing collaboration between Curium and Lantheus for targeted positron emission tomography (PET) for prostate cancer
- Deep learning platform to standardize comprehensive reporting in Europe
PARIS, July 25, 2023 (GLOBE NEWSWIRE) — Curium, the world leader in nuclear medicine, today announced a ‘licensing and development’ agreement with EXINI Diagnostics AB, a Lantheus company (EXINI), to customize EXINI’s artificial intelligence (AI) platform for use in Europe. The agreement builds on the existing collaboration in PET scan-guided prostate cancer between Curium and Lantheus with an exclusive licensing and development agreement for AI-assisted quantitative analysis and standardized reporting of PSMA PET/CT image assessments.
Advertising 2
This ad hasn’t been uploaded yet, but your article continues below.
Article content
Article content
Today’s announcement follows a decision of the European Medicines Agency’s Committee for Medicinal Products for Human Use in May 2023 which recommended that PYLCLARI be granted a marketing authorization.® (bifluvastat)18F)) is intended for the diagnosis of prostate cancer.
Under the terms of the agreement, EXINI’s deep learning platform will be designed to meet the specific needs of the European market. The platform’s clinical value proposition is to increase the efficiency and reproducibility of PSMA PET/CT image assessments in prostate cancer and to set a standard for comprehensive reporting across the US and Europe. The deep learning algorithm will be trained on anonymized data from the Curium European Phase III PYTHON (NCT04734184) clinical trial, as well as the existing dataset from the two US registry studies (OSPREY – NCT02981368 and CONDOR – NCT03739684) of piflufolastat F18.
Article content
Advertising 3
This ad hasn’t been uploaded yet, but your article continues below.
Article content
AI-assisted assessment will help achieve more consistency, reliability and efficiency in reporting the overall PSMA-starved disease burden and in monitoring its change with treatments.
Benoit Woessmer, CEO of PET Europe at Curium, commented: “By leveraging artificial intelligence and extensive anonymized data from our European PYTHON clinical trial, this is an important milestone in advancing the diagnosis of prostate cancer, and indeed for the patients themselves. We are excited to use deep learning to help us redefine the cancer experience through our trusted legacy in nuclear medicine.”
Etienne Montagut, Chief Business Officer at Lantheus, commented: “PSMA PET has had an important impact on the management of prostate cancer. With the expansion of treatment options in prostate cancer, including PSMA RLT, there is an increasing demand for effective and standardized quantitative assessment of the disease burden of PSMA. Our partnership with Curium expands the patient data set that informs our AI algorithm and enables broader access to our programs.”
Advertising 4
This ad hasn’t been uploaded yet, but your article continues below.
Article content
About Corium
Curium is a global leader in nuclear medicine. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the world. Our proven heritage combined with a pioneering approach are the hallmarks of delivering innovation, excellence and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and radiotherapeutic solutions for life-threatening diseases to more than 14 million patients annually. The name “Cureum” honors the legacy of pioneering radioactive material researchers Marie and Pierre Curie, after whom the radioactive element Curium is named and underscores our focus on nuclear medicine. To learn more, visit curiumpharma.com.
for more information:
Ross Bethel
Vice President, Head of Global Communications
Communications@curiumpharma.com
comments
Postmedia is committed to maintaining an active and civil forum for discussion and encouraging all readers to share their opinions on our articles. Comments may take up to an hour to be moderated before they appear on the site. We ask that you keep your comments relevant and respectful. We’ve enabled email notifications – you’ll now receive an email if you get a response to your comment, if there’s an update to a comment thread you’re following or if it’s a user you’re following. Visit our Community Guidelines for more information and details on how to adjust your email settings.
Join the conversation